A Phase 1/2, Open-Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 (Recombinant AAV2/6 Human Factor 8 Gene Therapy) in Adult Subjects With Severe Hemophilia A

Trial Profile

A Phase 1/2, Open-Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 (Recombinant AAV2/6 Human Factor 8 Gene Therapy) in Adult Subjects With Severe Hemophilia A

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs SB 525 (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sangamo Therapeutics
  • Most Recent Events

    • 08 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 07 Jun 2017 According to a Sangamo Therapeutics media release, initial data from this study are expected in late 2017 or early 2018.
    • 16 May 2017 According to a Sangamo Therapeutics media release, this trial is expected to open and begin screening subjects for enrollment by the end of the second quarter 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top